TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9925061
Drug: n of
Normalized name: Antigen of mold
Approvals — FDA: no, EMA: no, PMDA: no
Description: n of 1 trials (theophylline treatment)
Study: 8542870
Drug: Hirudin (DG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (DG I: bolus 0.1 mg.kg‐1 and continuous infusion 0.06 mg.kg‐1.h‐1)
Study: 8542870
Drug: Hirudin (DG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (DG II: bolus 0.2 mg.kg‐1.h‐1)
Study: 8542870
Drug: Hirudin (DG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (DG III: bolus 0.4 mg.kg‐1 with 0.15 mg.kg‐1.h‐1)
Study: 8542870
Drug: Heparin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin as an adjunct to streptokinase and aspirin (control group)
Study: 30537083
Drug: Fimasartan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (60 mg once a day)
Study: 8228208
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg once a day)
Study: 28691132
Drug: Topical pure
Normalized name: Dream Pure BB Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pure emu oil
Study: 25445556
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (SRT) at 66 Gy to the prostate bed, median 86 days after RP
Study: 25445556
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (SRT)
Study: 23806773
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZA) 4 mg administered within 28 days pre-HCT and at 3 and 6 months after HCT
Study: 23806773
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZA)
Study: 23806773
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium carbonate and vitamin D supplements)
Study: 11709314
Drug: Ritonavir-saquinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-saquinavir (400 mg b.i.d.)
Study: 11709314
Drug: Ritonavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (600 mg b.i.d.)
Study: 3131251
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. (n = 40)
Study: 3131251
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 2 g t.i.d. (n = 40)
Study: 29657147
Drug: Subcutaneous Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous Abatacept (ABA) 125 mg/wk
Study: 29657147
Drug: Intravenous Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Abatacept (ABA)
Study: 28511482
Drug: ketofol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketofol (25 mg ketamine plus 25 mg propofol)
Study: 28511482
Drug: ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine (0.25 mg/kg)
Study: 28511482
Drug: propofol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol (0.25 mg/kg)
Study: 23325368
Drug: SPST (independent
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPST (independent of treatment)
Study: 9264578
Drug: Intraperitoneal FUDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal FUDR + cisplatin (60 mg/m2 in 500 mL of NS)
Study: 8495682
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole 40 mg the evening before surgery
Study: 8495682
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole 40 mg 2 h before surgery
Study: 8495682
Drug: Effervescent cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent cimetidine 800 mg, 2 h before surgery
Study: 8495682
Drug: No antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antacid (control group)
Study: 28396179
Drug: Dance group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance group (60 minutes weekly for 40 weeks)
Study: 28396179
Drug: Music group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music group (60 minutes weekly for 40 weeks)
Study: 26568937
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 20 mg/kg
Study: 26568937
Drug: Local bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local bupivacaine 2.5 ml 0.25%
Study: 26568937
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine 1 mg/kg
Study: 21150717
Drug: WT1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1 peptide vaccine and gemcitabine (GEM) combination therapy
Study: 16799184
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline gel) dressing
Study: 16799184
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma gel (after adjusting for wound size outliers)
Study: 11167236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bacitracin and neomycin
Study: 8901773
Drug: rPF4 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPF4 (1.0 mg/kg IV over 2 minutes)
Study: 8901773
Drug: Protamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine (50 mg IV over 10 minutes)
Study: 7045754
Drug: Cefoxitin (2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2-dose course)
Study: 27636836
Drug: Segmental traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental traction therapy along with conventional physiotherapy, 15 sessions, 5 times a week for 3 weeks.
Study: 21878941
Drug: cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib 20 mg per day plus carboplatin and paclitaxel
Study: 21878941
Drug: cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib 20 mg per day followed by cediranib (concurrent plus maintenance)
Study: 15455650
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine supplementation (240 ml/day) with MD
Study: 15455650
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine supplementation (240 ml/day) with HFD
Study: 11432629
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (MMM chemotherapy for ER-negative patients: methotrexate 30 mg/m2, mitozantrone 7 mg/m2, mitomycin 7 mg/m2 every three weeks for three months; Goserelin 3.75 mg monthly for premenopausal ER-positive patients; Formestane 250 mg every two weeks for postmenopausal ER-positive patients)
Study: 3139776
Drug: Aluminum hydroxide-adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide-adsorbed vaccine (25 micrograms protein and polysaccharide administered intramuscularly)
Study: 27625344
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg Q4W
Study: 21192125
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment (Depotrex; Biotek, Inc.)
Study: 19876678
Drug: 3-week 10-Hz
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy, 15 sessions per 3 weeks, 1,000 stimuli per session, stimulation intensity 110% of the individual motor threshold
Study: 19876678
Drug: 3-week 10-Hz
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy
Study: 1635654
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of lidocaine (xylocaine spray)
Study: 6366248
Drug: Magnesium-containing Collins'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-containing Collins' 2 solution
Study: 6366248
Drug: Magnesium-free Euro-Collins'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-free Euro-Collins' solution
Study: 29246745
Drug: LSE liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSE liposomal gel
Study: 20167430
Drug: Intradiscal methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal methylene blue injection
Study: 25550680
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg.kg(‐1))
Study: 25550680
Drug: Midazolam (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.025 μg.kg(‐1))
Study: 18507654
Drug: Domperidone 30
Normalized name: domperidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 30 mg daily
Study: 18507654
Drug: Domperidone 60
Normalized name: domperidone 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 60 mg daily
Study: 2370924
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (nifedipine)
Study: 363104
Drug: N-n-propyl norapomorphine
Normalized name: n-propyl paraben
DrugBank: Propylparaben (DB14177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-n-propyl norapomorphine (NPA) with suboptimal doses of levodopa
Study: 23683600
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of teriparatide (20 μg daily) and denosumab (60 mg every 6 months)
Study: 25043459
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of teriparatide and denosumab
Study: 8064552
Drug: Topical liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposome system bearing local anaesthetic lignocaine
Study: 8064552
Drug: Conventional topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical application
Study: 118360
Drug: Acetyldigoxin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyldigoxin (0.4 mg/day)
Study: 118360
Drug: Acetyldigoxin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyldigoxin (0.4 mg/day) + Hydergin (3 mg/day)
Study: 31238507
Drug: 60-g faecal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-g faecal microbiota transplantation (FMT)
Study: 24718886
Drug: Panitumumab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab 6.0 mg/kg every 2 weeks + FOLFOX4
Study: 15339468
Drug: Sansheng Huatan
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sansheng Huatan Decoction combined with chemotherapy
Study: 12700441
Drug: sultamicillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sultamicillin (2 x 375 mg orally)
Study: 12700441
Drug: amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin (3 x 500 mg orally)
Study: 9627822
Drug: Implosive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implosive therapy (IT)
Study: 8088611
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (ip): cisplatin 200 mg/m2 plus etoposide 350 mg/m2 every 4 weeks for six cycles.
Study: 8088611
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (iv): cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks for six cycles.
Study: 8088611
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (ip)
Study: 8088611
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (iv)
Study: 2779810
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/h
Study: 2779810
Drug: Buprenorphine 0.03
Normalized name: buprenorphine 0.035 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.03 mg/h
Study: 1108581
Drug: 1.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg/kg of 0.5% plain bupivacaine
Study: 1108581
Drug: 2.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mg/kg of 1.0% plain etidocaine
Study: 27848196
Drug: LT4 oral
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 oral liquid formulation (SOL)
Study: 27848196
Drug: LT4 tablet
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 tablet formulation (TAB)
Study: 27848196
Drug: LT4 formulations
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 formulations (TAB and SOL)
Study: 11029005
Drug: Supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised treatment interruptions (one or two)
Study: 21962393
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (thalidomide plus dexamethasone)
Study: 16382442
Drug: Ouabain infusion
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ouabain infusion (0.4 mug.min(‐1).dl(‐1))
Study: 16382442
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ouabain infusion)
Study: 12805250
Drug: Enriched drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched drink with essential vitamins and minerals (30% to 150% of RDA and higher levels of antioxidants), taken twice a day for six months
Study: 12805250
Drug: Placebo drink,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink, taken twice a day for six months
Study: 12768686
Drug: Partial laryngectomy
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial laryngectomy with preoperative radiotherapy (dose 40-50Gy)
Study: 12768686
Drug: Partial laryngectomy
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial laryngectomy with postoperative radiotherapy (dose 51-70 Gy)
Study: 2065035
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg simvastatin q.a.m.
Study: 2065035
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg simvastatin q.p.m.
Study: 2065035
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg simvastatin q.a.m.
Study: 2065035
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg simvastatin q.p.m.
Study: 6127790
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with propantheline and antacids
Study: 6127790
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with cimetidine and antacids
Study: 6127790
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (unspecified)
Study: 31780277
Drug: Standard-dose indometacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose indometacin (two 50 mg suppositories + placebo)
Study: 31780277
Drug: High-dose indometacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose indometacin (three 50 mg suppositories + additional 50 mg after 4 hours)
Study: 31780277
Drug: Standard-dose indometacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose indometacin
Study: 31780277
Drug: High-dose indometacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose indometacin
Study: 28093625
Drug: Ultralow dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow dose CT (0.13 ± 0.01 mSv)
Study: 28093625
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CT (1.8 ± 0.7 mSv)
Study: 26082615
Drug: Fimasartan/HCTZ 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan/HCTZ 12.5 mg
Study: 22168805
Drug: 2.84 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.84 mL of lidocaine with epinephrine plus 0.5 M mannitol
Study: 22168805
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of lidocaine with epinephrine plus 0.5 M mannitol
Study: 22168805
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of lidocaine with epinephrine (control solution)
Study: 22168805
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine formulations without mannitol
Study: 3533085
Drug: suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprofen 200 mg/ml
Study: 3533084
Drug: lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysine acetylsalicylate 0.9 g/2.5 ml
Study: 30337745
Drug: Oxygen drive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol for 3 days before operation
Study: 30337745
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without preoperative aerosol inhalation
Study: 30337745
Drug: Oxygen drive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol
Study: 27048692
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy in patients without intravenous alteplase treatment
Study: 27048692
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy in patients with intravenous alteplase treatment
Study: 24329132
Drug: Medium-dose ultrasound
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ultrasound (1.5 Watt/cm(2))
Study: 24329132
Drug: Low-dose ultrasound
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ultrasound (0.5 W/cm(2))
Study: 18449450
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) 0.6-0.8 g/kg per day
Study: 18449450
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NPD) 1.0-1.2 g/kg per day
Study: 8618369
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate antacid tablets (Tums, 1000 mg)
Study: 8618369
Drug: Famotidine (Pepcid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (Pepcid AC, 10 mg)
Study: 1565534
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral cefixime (8 mg/kg)
Study: 1565534
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral trimethoprim/sulfamethoxazole (TMP/SMX) (8/40 mg/kg/day)
Study: 31564601
Drug: Tu Salud
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tu Salud ¡Si Cuenta! (Your Health Matters!) at Home Intervention, 6 monthly CHW visits
Study: 29771700
Drug: IV amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amino acid supplementation (up to 100g daily to achieve 2.0g/kg/d)
Study: 27278405
Drug: Polyphenol- and
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol- and fibre-rich foods (PFRF) - lower dose
Study: 27278405
Drug: Polyphenol- and
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol- and fibre-rich foods (PFRF) - higher dose
Study: 16084125
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg melatonin
Study: 10713863
Drug: Rhinogen (hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinogen (hyaluronic acid containing cream)
Study: 10713863
Drug: H.E.C. (ointment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.C. (ointment)
Study: 7586621
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (5 micrograms/kg/min i.v. for a median of 109 hours)
Study: 7586621
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (continued)
Study: 7586621
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (continued and interrupted)
Study: 1735342
Drug: Percutaneous drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous drainage using ultrasound guidance followed by intralesional nitroimidazole administration
Study: 1735342
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with nitroimidazoles
Study: 20581302
Drug: Surgical management,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical management, radiation therapy, and systemic therapy for pelvic bone sarcomas
Study: 17593235
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (0.2 U/kg)
Study: 17593235
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.2 U/kg)
Study: 17593235
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (0.4 U/kg)